Company intelligence / Profile preview
NeuDirection
London, London, United Kingdomneudirection.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NeuDirection is a clinical-stage biotechnology company focused on developing disease-modifying therapies for Parkinson's disease. Its lead program, ND-001 (a high-dose formulation of ambroxol), is being evaluated in the Phase 3 ASPIRE-PD clinical trial. The therapy acts as a pharmacological chaperone to increase the activity of the glucocerebrosidase (GBA) enzyme, aiming to clear alpha-synuclein aggregates and slow disease progression.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Cure Parkinson'sMichael J. Fox FoundationVan Andel InstituteUniversity College London
Beyond the preview
Go deeper on NeuDirection.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuDirection.